Pharma is innovating to hit even more targets The latest article I saw about the work being done in this class is a study in mice looking at a quintuple agonist (5 different targets!) I almost never write about mice studies because of how preliminary they are and how unlikely a finding in mice is to ever translate into anything useful in humans, but because of the success weve already seen of this drug class as well as the way that hitting more pathways seems to increase efficacy, I thought this was research worth highlighting
Liraglutide, with a more mature manufacturing pipeline, was often available when Wegovy was not
& Coloff, J
Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app, demonstrating the benefits of combining GLP-1 medication with Nooms GLP-1 Companion behavior-change program PRINCETON, N.J., February 4, 2026 Noom, the leading behavior change company, today shared new real-world findings from tens of thousands of members, showing a clear relationship: members who engage more with Nooms leading GLP-1 Companion app tend to lose more weight and stay on a medication program longer
Insert the needle into your skin at a 90-degree angle to prevent leakage, pressing down firmly until the yellow bar stops moving
Pregnant women with questions about Zofran should talk to their doctors